Akebia Therapeutics (AKBA) closed at $0.71 on October 30, 2026, down 4.8% from the previous close, on volume of 2,645,581 shares (30-day average 7,789,959).
Data as of October 30, 2026.
30-Oct-2026
Russell 2000 estimated to drop 83 stocks in December rebalance - Stephens
Seeking Alpha News (Thu, 29-Oct 3:44 PM ET)
Globe Newswire (Thu, 29-Oct 8:00 AM ET)
Globe Newswire (Mon, 26-Oct 9:20 AM ET)
Globe Newswire (Wed, 7-Oct 8:00 AM ET)
Globe Newswire (Tue, 6-Oct 8:00 AM ET)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Thu, 1-Oct 4:05 PM ET)
Globe Newswire (Mon, 14-Sep 8:00 AM ET)
Globe Newswire (Tue, 1-Sep 8:00 AM ET)
Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
Globe Newswire (Wed, 5-Aug 4:05 PM ET)
Globe Newswire (Mon, 3-Aug 8:00 AM ET)
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
Akebia Therapeutics trades on the NASDAQ stock market under the symbol AKBA.
As of October 30, 2026, AKBA stock price declined to $0.71 with 2,645,581 million shares trading.
AKBA has a beta of -0.41, meaning it tends to be less sensitive to market movements. AKBA has a correlation of 0.00 to the broad based SPY ETF.
AKBA has a market cap of $195.78 million. This is considered a Micro Cap stock.
Last quarter Akebia Therapeutics reported $49 million in Revenue and -$.03 earnings per share. This fell short of revenue expectation by $-390,960 and met earnings estimates .
In the last 3 years, AKBA traded as high as $4.08 and as low as $.54.
The top ETF exchange traded funds that AKBA belongs to (by Net Assets): VTI, IWM, VXF, IWO, FESM.
AKBA has underperformed the market in the last year with a return of -66.4%, while the SPY ETF gained +12.3%. In the last 3 month period, AKBA fell short of the market, returning -47.7%, while SPY returned +2.1%. However, in the most recent 2 weeks AKBA has outperformed the stock market by returning +5.4%, while SPY returned -1.0%.
AKBA support price is $.70 and resistance is $.78 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AKBA shares will trade within this expected range on the day.
